Epilepsy – UCB EP0162

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

Inclusion Criteria:

• Participant must be ≥12 years of age at the Baseline/Randomization Visit
• Participant must have a study caregiver ≥18 years of age at the Screening Visit
• Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures
• Other criteria may apply

Call us at 619-489-5613 or complete the form and our team will reach out soon to help determine your eligibility.